Search results
Restless Legs Syndrome: What to Know in Primary Care
Medscape· 3 days agoAs a result of this ongoing sleep disturbance, Laura feels tired all the time and is struggling to fulfill her work commitments. Laura probably has a restless legs syndrome (RLS). What do we ...
‘Safety bundles’ may reduce pregnancy-related deaths, particularly among Black women
The Myrtle Beach Sun News· 3 days agoA woman begins losing blood during childbirth. Excessive blood loss is the leading cause of death for women on the day they give birth and one of the leading causes of maternal death in the postpartum period.
New Clinical Guidance for Sjögren-Related Neuropathy
Medscape· 21 hours agoNew guidelines to manage peripheral neuropathy related to Sjogren disease have been developed by a multidisciplinary team of physicians from across...
15 Breastfeeding Myths That It's Time to Stop Believing
Well and Good· 5 days agoBreastfeeding—it's a topic people are very opinionated about. But what info is true, and what are...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
WTNH-TV New Haven· 5 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study...
How to Wash Fruits and Veggies Efficiently and Inexpensively
Mercola· 19 hours agoNowadays, however, there are a few other things besides dirt to consider when getting your produce ready to eat. Pesticide residue is a common term today, unfortunately, and ...
Ask the Doc: Every Child can Benefit from Immunization
Stars and Stripes· 6 days agoMany dangerous, and once common, diseases have nearly disappeared from the United States because of...
'Safety bundles' may reduce pregnancy-related deaths, particularly among Black women
San Francisco Chronicle· 3 days agoA woman begins losing blood during childbirth. Excessive blood loss is the leading cause of death for women on the day they give birth and one of the leading causes of maternal death in the ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
Quad-City Times· 5 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
The Journal Times· 5 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study...